Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
Pulmatrix, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 17, 2017. The filing reports the entry into a material definitive agreement to facilitate the sale of the Company's common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial figure disclosed is the maximum aggregate offering amount of $11,000,000 for the sale of common stock under a new At-The-Market Sales Agreement.
Material Changes
On March 17, 2017, the Company entered into an At-The-Market Sales Agreement with BTIG, LLC. Key terms include:
- Offering Size: Up to $11,000,000 of common stock.
- Sales Agent: BTIG, LLC.
- Commission: BTIG will receive a commission equal to 3.0% of the gross proceeds from sales.
- Method: Shares will be sold on the NASDAQ Global Market, other trading markets, or through market makers/electronic communications networks.
- Termination: The agreement terminates automatically upon the sale of $11,000,000 worth of shares or earlier if terminated by the Company or BTIG.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary regarding future performance. The Company has agreed to indemnify BTIG against certain liabilities, including those under the Securities Act of 1933. The sale of shares is subject to the Company's existing shelf registration statement on Form S-3 (File No. 333-212546).
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $11,000,000 of stock.
- Review the full text of the At-The-Market Sales Agreement (Exhibit 1.1) for specific termination rights and covenants.
- Confirm the status of the Company's shelf registration statement (File No. 333-212546).
- Assess the Company's current cash position to determine the necessity of this capital raise.